Srivandana Akshintala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Srivandana Akshintala has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Brigitte C. Widemann
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland
51 shared publications - John W. Glod
National Cancer Institute, Center for Cancer Research, Pediatric Oncology Branch: Building 10 Center Drive, Rm 1-3752, Bethesda, MD, 20892
49 shared publications - Andrea M. Gross
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
47 shared publications - Alexander Pan
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 1
46 shared publications - Christine M. Heske
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
46 shared publications - Donna Bernstein
Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, Maryland
46 shared publications
Latest Publications
- 18 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium
Malignant peripheral nerve sheath tumors (MPNST) are soft tissue sarcomas, occurring either in people with neurofibromatosis type 1 (NF1) or sporadically, with a tendency for recurrence and distant metastases and poor survival rates. The only proven curative treatment is complete oncologic resection, and there is currently no FDA-approved drug for the treatment of MPNST. Multiple clinical trials have failed to achieve improvement in survival, and novel therapeutic approaches are urgently needed. To address this need, members of the MPNST Committee of the Congressionally Directed Medical Research Programs-supported Neurofibromatosis Clinical Trials Consortium convened to develop a framework to prioritize therapeutic agents with the highest potential for successful clinical development. We review the potential agents that may be prioritized and propose a methodology to evaluate available preclinical and clinical data. Increasing the availability and use of diverse preclinical models and defining the best preclinical endpoints prior to clinical translation can increase the success of clinical trials. Subsequently, utilizing a platform trial design can accelerate the clinical development process and facilitate patient accrual. It is imperative to foster collaborations with pharmaceutical companies and community partners. The integration of preclinical and clinical evaluation in an iterative and informative process can accelerate effective clinical development.
- 18 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium
Malignant peripheral nerve sheath tumors (MPNST) are soft tissue sarcomas, occurring either in people with neurofibromatosis type 1 (NF1) or sporadically, with a tendency for recurrence and distant metastases and poor survival rates. The only proven curative treatment is complete oncologic resection, and there is currently no FDA-approved drug for the treatment of MPNST. Multiple clinical trials have failed to achieve improvement in survival, and novel therapeutic approaches are urgently needed. To address this need, members of the MPNST Committee of the Congressionally Directed Medical Research Programs-supported Neurofibromatosis Clinical Trials Consortium convened to develop a framework to prioritize therapeutic agents with the highest potential for successful clinical development. We review the potential agents that may be prioritized and propose a methodology to evaluate available preclinical and clinical data. Increasing the availability and use of diverse preclinical models and defining the best preclinical endpoints prior to clinical translation can increase the success of clinical trials. Subsequently, utilizing a platform trial design can accelerate the clinical development process and facilitate patient accrual. It is imperative to foster collaborations with pharmaceutical companies and community partners. The integration of preclinical and clinical evaluation in an iterative and informative process can accelerate effective clinical development.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Supplemental Protocol Information. A: Study Eligibility; B: Dasatinib dosing nomogram; C: Dasatinib dose modifications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Summary statistics for nucleosome footprints at YES1 and IGF1R regulatory motifs
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Summary statistics for nucleosome footprints at YES1 and IGF1R regulatory motifs
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Progression-free survival for full cohort of patients (A) and by dose level (B).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Progression-free survival for full cohort of patients (A) and by dose level (B).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Serial samples demonstrate recurrent loci with copy number alterations for each patient.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Serial samples demonstrate recurrent loci with copy number alterations for each patient.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Adverse events possibly probably or definitely related to dasatinib across all 28 cycles (maximum grade per patient)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Adverse events possibly probably or definitely related to dasatinib across all 28 cycles (maximum grade per patient)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Tumor fractions from plasma cfDNA.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Tumor fractions from plasma cfDNA.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Fusion-positive RMS enhancer sites; Universal DNAase-hypersensitivity sites; YES1 and IGF1R region sets
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Fusion-positive RMS enhancer sites; Universal DNAase-hypersensitivity sites; YES1 and IGF1R region sets